Drug Profile


Alternative Names: NPSP790; SB-423557

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NPS Pharmaceuticals
  • Developer Shire
  • Class Osteoporosis therapies; Small molecules
  • Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Hypocalcaemia
  • Discontinued Osteoporosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypocalcaemia(In volunteers) in USA (PO)
  • 21 Feb 2015 NPS Pharmaceuticals has been acquired by Shire
  • 03 Aug 2011 423557 is no longer licensed to GlaxoSmithKline worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top